Conditions · Pancreatic cancer
Pancreatic cancer — clinical trials in France
Prefer to look first? Browse the live map without signing up.
30 open options
- TRIALNARECRUITING
RPSA as a Potential Prognostic Biomarker of Pancreatic Cancer
Blood sample — 1 site
- TRIALPHASE1RECRUITING
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
ASP2138 · Pembrolizumab · Oxaliplatin — 46 sites
- TRIALNARECRUITING
Impact of Non-magnetic Screen Respiratory Self-guidance During MRI-guided Radiotherapy Sessions for Mobile Lesions
With non-magnetic screen — 1 site
- TRIALPHASE2RECRUITING
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Belzutifan — 84 sites
- TRIALPHASE1RECRUITING
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Sofe-M · bevacizumab · carboplatin — 24 sites
- TRIALNARECRUITING
Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC)
Detection of circulating tumor cells expressing Axl: CTC-AXL(+) — 1 site
- TRIALPHASE1RECRUITING
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
INCB161734 · Cetuximab · Retifanlimab — 34 sites
- TRIALPHASE1RECRUITING
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
LY4052031 — 39 sites
- TRIALPHASE1RECRUITING
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
AMG 410 · Pembrolizumab · Panitumumab — 39 sites
- TRIALPHASE3RECRUITING
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
Ersodetug — 13 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
ponsegromab · placebo — 223 sites
- TRIALPHASE3RECRUITING
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Paltusotine · Placebo — 73 sites
- TRIALNARECRUITING
POP-UP: a Single-arm, Two-cohort Study: an 8-week Trimodal Pre-habilitation Program for Patients With Pancreatic Ductal Adenocarcinoma and Oesogastric
Prehabilitation program — 11 sites
- TRIALPHASE2 / PHASE3RECRUITING
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Zanzalintinib · Everolimus — 126 sites
- TRIALNARECRUITING
Pancreatic Radiofrequency Under High Echo-endoscopy in the Management of Pancreatic Neuroendocrine Tumors
Radiofrequency ablation — 1 site
- TRIALNARECRUITING
Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Reducing Fatigue 3 Months After Adjuvant Chemotherapy for Cancer
APA program — 1 site
- TRIALNARECRUITING
Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
Stereotactic body radiotherapy · Palliative RT — 13 sites
- TRIALPHASE2RECRUITING
Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Gabrinox · MRI-GUIDED STEREOTACTIC RADIOTHERAPY — 9 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
Risvutatug Rezetecan · Drug 1 · Drug 2 — 85 sites
- TRIALPHASE2RECRUITING
Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)
68Ga-FAPI-46 for PET / CT scan — 1 site
- TRIALPHASE2RECRUITING
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
BAY2927088 — 54 sites
- TRIALPHASE2 / PHASE3NOT_YET_RECRUITING
Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for Cancer
Comprehensive Geriatric Assessment — 12 sites
- TRIALNARECRUITING
Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients
Tumor samples (archival FFPE and optional de novo biopsy) and blood samples — 1 site
- TRIALPHASE2RECRUITING
Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy
FOLFIRINOX treatment — 1 site
- TRIALPHASE1RECRUITING
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
DSB2455 — 21 sites
- TRIALPHASE1RECRUITING
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Darlifarnib · Cabozantinib · Adagrasib — 38 sites
- TRIALPHASE1RECRUITING
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
LY3962673 · Cetuximab · Gemcitabine — 52 sites
- TRIALPHASE2NOT_YET_RECRUITING
Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers
standard radiotherapy with chemotherapy · MRI-guided adaptive stereotactic radiotherapy (SMART) — 17 sites
- TRIALNARECRUITING
Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of Cancer
educational workshop on nutrition + additional intervention on UPF tool and how to use it — 3 sites
- TRIALNARECRUITING
Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients
Analyze of GemCore status — 1 site
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.